Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses
Abstract Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fukuma, Nobuaki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.07.27.453843 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032275889 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032275889 | ||
| 003 | DE-627 | ||
| 005 | 20240424105214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210729s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.27.453843 |2 doi | |
| 035 | |a (DE-627)XBI032275889 | ||
| 035 | |a (biorXiv)10.1101/2021.07.27.453843 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fukuma, Nobuaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Hulke, Michelle L. |e verfasserin |0 (orcid)0000-0001-7607-9315 |4 aut | |
| 700 | 1 | |a Brener, Michael I. |e verfasserin |4 aut | |
| 700 | 1 | |a Golob, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Zilinyi, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tzimas, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Ilaria |e verfasserin |0 (orcid)0000-0001-6432-3798 |4 aut | |
| 700 | 1 | |a McGroder, Claire |e verfasserin |0 (orcid)0000-0003-1157-4627 |4 aut | |
| 700 | 1 | |a Pfeiffer, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Geping |e verfasserin |4 aut | |
| 700 | 1 | |a Burkhoff, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Martin B. |e verfasserin |4 aut | |
| 700 | 1 | |a Maurer, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Moses, Jeffrey W. |e verfasserin |4 aut | |
| 700 | 1 | |a Uhlemann, Anne-Catrin |e verfasserin |0 (orcid)0000-0002-9798-4768 |4 aut | |
| 700 | 1 | |a Hibshoosh, Hanina |e verfasserin |4 aut | |
| 700 | 1 | |a Uriel, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Szabolcs, Matthias J. |e verfasserin |4 aut | |
| 700 | 1 | |a Redfors, Björn |e verfasserin |4 aut | |
| 700 | 1 | |a Marboe, Charles C. |e verfasserin |4 aut | |
| 700 | 1 | |a Baldwin, Matthew R. |e verfasserin |0 (orcid)0000-0003-4670-3433 |4 aut | |
| 700 | 1 | |a Tucker, Nathan R. |e verfasserin |0 (orcid)0000-0002-5071-4218 |4 aut | |
| 700 | 1 | |a Tsai, Emily J. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1172/jci.insight.154633 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.27.453843 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||